Granocyte (Lenograstim)

Granocyte is indicated for the prevention and treatment of neutropenia in specific clinical situations.

• Chemotherapy‑induced neutropenia in adult patients.
• Neutropenia associated with high‑dose chemotherapy for stem cell mobilization.
• Neutropenia following autologous or allogeneic bone‑marrow transplantation.
• Situations where rapid neutrophil recovery is clinically desired.

The safety profile of lenograstim includes a range of observed adverse events, which are generally categorized by frequency.

Common

• Bone pain, especially in the lower back or limbs.
• Injection site reactions such as erythema, swelling, or tenderness.
• Mild fever or flu‑like symptoms.
• Headache or fatigue.

Serious

• Splenic rupture or enlargement.
• Severe allergic reactions including anaphylaxis.
• Acute respiratory distress or pulmonary edema.
• Rapid increase in white blood cell count (leukocytosis) with potential complications.

Before initiating Granocyte, clinicians should evaluate several precautionary factors to minimize risk.

• Known hypersensitivity to lenograstim or any excipients.
• History of splenic disorders or prior splenic injury.
• Active uncontrolled infections, especially bacterial.
• Concurrent use of other hematopoietic growth factors.
• Pregnancy or breastfeeding status, as safety data are limited.
• Renal or hepatic impairment may require monitoring.

Lenograstim may interact with other agents; awareness of potential interactions helps guide safe co‑administration.

Avoid

• Concurrent administration of other G‑CSF products (e.g., filgrastim, pegfilgrastim).
• Live vaccines during active treatment, due to altered immune response.

Use with caution

• Chemotherapeutic agents that cause profound myelosuppression.
• Corticosteroids, which may potentiate neutrophil effects.
• Anticoagulants, as neutrophil activation can influence coagulation.